A real-world study on SGLT2 inhibitors and diabetic kidney disease progression.

Allen Yan Lun LiuSerena LowEster YeohEng Kuang LimClaude Jeffrey RenaudSelene Tse Yen TeohGrace Feng Ling TanChung Cheen ChaiBo LiuTavintharan SubramaniamChee Fang SumJian-Jun Liu

Published in: Clinical kidney journal (2022)

This real-world study demonstrates the benefits of SGLT2is on CKD progression and ESKD. The effect is more pronounced in moderate to advanced CKD patients.

Keyphrases

chronic kidney disease
end stage renal disease
newly diagnosed
prognostic factors
patient reported outcomes